Refine by
Brain Blood Articles & Analysis: Older
49 news found
This innovative platform is specifically designed to overcome the primary challenge in treating brain diseases: the blood-brain barrier (BBB). By leveraging a suite of biomimetic and AI-powered technologies, BBBporter™ enables the efficient transport of therapeutic candidates into the brain, opening new avenues for ...
About Nubeqa™ (darolutamide) Darolutamide is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells. The low potential for blood-brain barrier penetration for ...
ByBayer AG
About Nubeqa™(darolutamide) Darolutamide is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells. The low potential for blood-brain barrier penetration for ...
ByBayer AG
MET increases dwell time in the nares promoting delivery via the olfactory route across the blood brain barrier and into the central nervous ...
Currently, enkephalins are limited in their therapeutic potential by their pharmacokinetic profiles due to their inability to cross the blood-brain barrier to reach opioid receptors located in the central nervous system. ...
Historically, the blood-brain barrier has been a primary roadblock in delivering therapies, especially for larger molecules and cellular therapies, directly to the brain. ...
Working in collaboration with NRC’s Human Health Therapeutics Research Centre, the objectives of the project will be to further expand the translational research of OB-002, including an assessment of the molecules’ ability to cross the blood brain barrier (BBB). “We are very pleased to receive advisory services and this funding from NRC ...
He is also executive chairman of Cordance Medical, a company revolutionizing treatment of cancer, Alzheimer’s disease, and other brain disorders using non-invasive transcranial focused ultrasound to temporarily open the blood-brain-barrier. ...
ByElucid
Kurve Therapeutic’s patented intranasal drug delivery technology, Controlled Particle Dispersion® (CPD), has been shown to bypass the blood-brain barrier, delivering 30x more medication directly to the brain than infusions. Marc Giroux, Kurve Therapeutics CEO and founder said: “An IV infusion manages to deliver one-tenth of 1% ...
About Nubeqa (darolutamide) Darolutamide is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells. The low potential for blood-brain barrier penetration for darolutamide is ...
ByBayer AG
New Pathway Discovery - molecules bond and synergistically attach to Peroxisome proliferator-activated receptors (PPARs) allowing the formula to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. ...
New Pathway Discovery – molecules bond and synergistically attach to Peroxisome proliferator-activated receptors (PPARs) allowing the formula to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. ...
The main obstacle in treating neurodegenerative diseases such as Alzheimer’s has been penetrating the blood-brain barrier (BBB). In preliminary studies, Kurve’s patented Controlled Particle Dispersion® technology has been shown to bypass the blood-brain barrier and was able to deliver up to 30x more medication ...
About Nubeqa™ (darolutamide) Darolutamide is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells. The low potential for blood-brain barrier penetration for ...
ByBayer AG
TIGERTRIEVER 13 is the smallest revascularization device in the world to date and is designed to remove thrombus from delicate brain blood vessels during an ischemic stroke. It is the only device that adjusts to the vasculature and clot, a more atraumatic approach than existing devices. ...
Kurve Therapeutics has succeeded in bypassing the blood-brain barrier with their patented Controlled Particle Dispersion® (CPD) technology, creating new hope in the treatment of central nervous system disorders. ...
The Total Brain platform helps more than one million individuals improve overall mental health and brain performance using several semi-quantitative functional methods. The company’s data sets represent the world’s largest standardized brain database encompassing human electrical brain function, brain ...
Significant improvements in gait and wire hang functions after gene therapy were also observed seven months post gene therapy Additionally, glycogen was reduced >95% in the brain and >99% in the spinal cord, improving locomotor function and demonstrating that modified HSCs crossed the blood-brain barrier where their offspring produced ...
About Nubeqa™ (darolutamide) Darolutamide is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells. The low potential for blood-brain barrier penetration for ...
ByBayer AG
” It is well established that neurovascular dysfunction, blood–brain barrier (BBB) leakage, and persistent vascular- and neuro-inflammation are among the critical events that eventually lead to neurodegeneration. With the Inscopix platform now able to perform blood flow and neuronal imaging studies simultaneously within deep ...